800-872-2273

Clinical Trials and Studies

Your participation matters. Help us discover and cure!

Contact us at (800) USC-CARE (800-872-2273)

Pulmonary Arterial Hypertension (PAH) Quality Enhancement Research Initiative (QuERI) Extension Program

Description

This is a prospective, U.S.-based, multi-center, knowledge translation program tracking patient management until approximately early 2018. To improve the management of PAH patients through an evidence-based approach aimed at achieving optimal WHO functional class (FC). The goal of the optimal functional class is to improve WHO functional class III and IV patients to functional class I or II, and to improve all functional class II patients to functional class I, or at least to maintain functional class I/II in patients presenting in that functional class. Endpoints:1. Proportion of patients achieving guideline-recommended treatment at each documented visit.2. Proportion of patients achieving optimal functional class using an evidence-based reatment algorithm.3. Proportion of patients on various therapies in relation to their WHO functional class.4. PAH management (use of therapies) by physicians across patient risk strata based on FC.5. Association between treatment and physician and patient adherence with recommended treatment.6. Utilization of Knowledge Translation Program system reminders, and response by the physicians when asked for reasons evidence based therapy was not utilized.7. Survival by FC (baseline and change), etiology, prevalent vs incident, academic vs community, adherence and reminders.Descriptive analysis of demographic variables, physical exam, medical history and treatment profile will be performed as appropriate. Confidence Intervals (95%) will be calculated for descriptive and comparative purposes.

Phase

N/A

Inclusion and Exclusion Criteria

  • Male and female adults (>/= 18 years of age)
  • Documented diagnosis of pulmonary arterial hypertension (PAH) (all of the following): i. Right Heart Catheterization (RHC) demonstrating mean Pulmonary Arterial Pressure (mPAP) > 25mm Hg and Pulmonary Capillary Wedge Pressure (PCWP) ii. Forced Expiratory Volume in the first second (FEV1) > 50% predicted normal iii. Ventilation/Perfusion (V/Q) and/or Computerized Tomography (CT) scan excluding the thromboembolic etiology
  • Diagnosis of PAH < 3 years
  • Need for PAH specific treatment
  • Desire to participate and signs an Informed Consent.

  • Any of the criteria below:
  • Poor mental function, drug or substance (e.g., alcohol) abuse, or unstable psychiatric illness, which, in the opinion of the investigator, may interfere with optimal participation in the study;
  • Prior participation in this program; c. Patients with pulmonary hypertension classified as group 2
  • 5 Dana Point, 2008 updated clinical classification.

Sites

  • California

    • University of Southern California, Los Angeles, California, 90033
    • Harbor-UCLA Medical Center, Torrance, California, 90502
    • Alliance Medical and Research Center, Fountain Valley, California, 92866
    • Paloma Medical Group, San Juan Capistrano, California, 92675
    • Scripps Clinic, Scripps Green Hospital, La Jolla, California, 92037
    • Alta Bates Summit Medical Center, Berkeley, California, 94705
  • Nevada

    • The Lung Center of Nevada, Las Vegas, Nevada, 89128
  • Arizona

    • Pulmonary Associates, Phoenix, Arizona, 85006
  • Texas

    • El Paso Respiratory and Sleep Consultants, El Paso, Texas, 79902
    • Providence Health Center, Waco, Texas, 76712
    • UT Health - University of Texas Houston, Houston, Texas, 77030
    • Baylor College of Medicine, Houston, Texas, 77030
    • University of Texas Medical Branch, Galveston, Texas, 77555
  • Oregon

    • Heart Center Cardiology, Bend, Oregon, 97701
  • Colorado

    • South Denver Cardiology Associates PC, Littleton, Colorado, 80120
    • Robert E. Benkert, M.D.P.C., Wheatridge, Colorado, 80033
    • University of Colorado Denver, Aurora, Colorado, 80045
  • Washington

    • Cardiac Study Center, Puyallup, Washington, 98372
  • Nebraska

    • Nebraska Pulmonary Specialties, LLC, Lincoln, Nebraska, 68506
    • Creighton University Medical Centre - Pulmonary, Critical Care and Sleep Medicine Division, Omaha, Nebraska, 68131
  • South Dakota

    • Sioux Falls Cardiovascular PC, Sious Falls, South Dakota, 57103
  • Arkansas

    • University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205
  • Iowa

    • University of Iowa Hospitals & Clinics, Iowa City, Iowa, 52301
  • Louisiana

    • Ochsner Medical Center, New Orleans, Louisiana, 70121
  • Illinois

    • University of Illinois at Chicago, Chicago, Illinois, 60612
  • Alabama

    • University of South Alabama Medical Center, Mobile, Alabama, 36617
    • Cardiovascular Associates, PC, Birmingham, Alabama, 35216
  • Kentucky

    • University of Louisville School of Medicine, Louisville, Kentucky, 40202
    • Kentuckiana Pulmonary Associates, Louisville, Kentucky, 40202
  • Michigan

    • Spectrum Health, Grand Rapids, Michigan, 49525
  • Ohio

    • The Christ Hospital Heart & Vascular Center, Cincinnati, Ohio, 45219
    • University of Cincinnati Pulmonary Critical Care & Sleep Medicine, Cincinnati, Ohio, 45219
    • Dayton Respiratory Center, Dayton, Ohio, 45215
  • Georgia

    • Piedmont Healthcare, Atlanta, Georgia, 30309
Powered by SC CTSI